Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Mateos MV et al. Haematologica. 2014 Apr 24. [Epub ahead of print].

Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
Ahn SY et al. Ann Hematol. 2014 Apr 12. [Epub ahead of print].

Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation.
Chang WJ et al. Acta Haematol. 2014 Apr 8;132(2):226-232. [Epub ahead of print].

Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.
Ghosh N et al. Am J Hematol. 2014 Apr 10. doi: 10.1002/ajh.23733. [Epub ahead of print].

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies.
Ria R et al. Clin Exp Med. 2014 Apr 11. [Epub ahead of print].

Effectiveness of an algorithm based approach to the utilization of plerixafor in patients undergoing chemotherapy based stem cell mobilization.
Chow E et al. Biol Blood Marrow Transplant. 2014 Apr 3. pii: S1083-8791(14)00196-7. doi: 10.1016/j.bbmt.2014.03.023. [Epub ahead of print].

Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma.
Vekemans MC et al. Br J Haematol. 2014 Apr 4. doi: 10.1111/bjh.12881. [Epub ahead of print].

Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Romano A et al. Eur J Haematol. 2014 Mar 27. doi: 10.1111/ejh.12325. [Epub ahead of print].